Bayer's Medrad to expand PAD offering with rumoured Pathway purchase
This article was originally published in Clinica
Executive Summary
Bayer Healthcare's imaging subsidiary Medrad has agreed to acquire peripheral arterial disease (PAD) treatment specialist Pathway Medical Technologies for $125m, according to unconfirmed media reports.